Comorbidity, toxicity & interactions
An evidence-ranked safety framework that distinguishes direct findings for concentrated 7-OH from broader kratom evidence and clinical extrapolation.
Comorbidity changes the threshold for caution
Data insufficient Direct evidence for concentrated commercial 7-OH in most special populations is absent or extremely limited. Keep visible what is known from 7-OH, what is known from botanical kratom, and what is extrapolation. E01E31E34
| Population or comorbidity | Principal concern | Evidence status and modification to approach |
|---|---|---|
| Chronic pain | Stopping a product without an analgesia plan can make pain, withdrawal, and return to opioid exposure difficult to disentangle. | Practice-based synthesis Assess pain function and treatment options alongside dependence care; do not treat pain as an afterthought. |
| Psychiatric illness | Anxiety, insomnia, dysphoria, agitation, hallucinations, or psychosis may reflect withdrawal, sleep loss, coexposure, medicines, or primary illness. | Emerging Screen for self-harm and severe mental-status change; do not convert a mechanism into a diagnosis of “serotonergic 7-OH withdrawal.” E01E28 |
| Respiratory disease, OSA, or COPD | Reduced ventilatory reserve and sedative co-use can magnify opioid respiratory effects. | Mechanistically plausible Use a lower threshold for urgent assessment and avoid sedative stacking. E23E24 |
| Renal impairment | Dehydration, electrolyte disturbance, altered metabolite clearance, and accumulation of adjunctive medicines may complicate care. | Data insufficient Direct 7-OH accumulation data are unavailable; tailor hydration, monitoring, and adjunctive medicines to renal function. |
| Older adults and frailty | Sedation, falls, delirium, orthostasis, constipation, urinary retention, polypharmacy, and limited reserve are plausible hazards. | Mechanistically plausible Lower the threshold for monitored care when frailty, cognitive impairment, organ disease, or limited home support is present. |
| Adolescents and young adults | No adequate paediatric pharmacokinetic or treatment studies address commercial 7-OH. | Data insufficient Use developmentally appropriate assessment, overdose prevention, mental-health and co-use screening, and specialist involvement within applicable consent law. |
Pregnancy and lactation: continuity, not abrupt unsupported withdrawal
Data insufficient Direct concentrated-7-OH pregnancy and lactation data are not available. Broader kratom case reports and a small systematic review describe maternal dependence and neonatal withdrawal after prenatal exposure, but cannot establish a direct high-dose 7-OH protocol. E34
Do not recommend abrupt unsupported withdrawal during pregnancy. Significant opioid dependence should be managed with pregnancy-capable addiction care under established opioid-use-disorder principles; buprenorphine or methadone may be appropriate, but no 7-OH-specific pregnancy induction protocol has been validated. Coordinate obstetrics, addiction medicine, paediatrics or neonatology, and pharmacy as needed. E34E51
Lactation evidence for direct high-dose 7-OH and related analogues remains insufficient. Use individualised specialist assessment, product and polysubstance review, and a neonatal plan—not reassurance based on a “natural” label. E34
Hepatic and renal risk: known product signals, uncertain 7-OH attribution
Emerging Kratom-associated liver injury is documented in broader product literature, including a U.S. prospective case series with frequent jaundice and hospitalisation. This concerns kratom products or mixtures, not confirmed isolated 7-OH; isolated-7-OH hepatotoxicity is not established. E31
For jaundice, dark urine, pruritus, persistent nausea, abdominal pain, or marked fatigue, obtain a broad exposure history and evaluate competing causes. Hepatic disease may alter exposure and metabolite formation; no validated direct-7-OH dose-adjustment rule exists. E19E31
Data insufficient Parent alkaloids undergo extensive metabolism, and urinary metabolites and conjugates are detected, but direct evidence defining 7-OH accumulation in renal failure is unavailable. Renal disease therefore changes supportive care and adjunctive-medication choices more confidently than it permits an alkaloid dosing rule. E17
Seizure and severe psychiatric presentations require a broad differential
Emerging Seizures, agitation, confusion, hallucinations, psychosis, and severe altered mental status appear in surveillance and case reports. They are serious signals, but single-agent causality is incomplete because coexposures, other withdrawals, sleep deprivation, and primary illness complicate cases. E01E28
Patients with epilepsy, structural brain disease, prior withdrawal seizures, heavy alcohol or benzodiazepine use, stimulant exposure, or medicines that lower seizure threshold warrant higher caution. Assess conventional causes and overlapping withdrawals rather than assuming 7-OH withdrawal alone explains a seizure; evidence does not support routine anticonvulsant prophylaxis for uncomplicated 7-OH withdrawal. E01E28
Likewise, severe affective or psychotic symptoms should prompt assessment for polysubstance exposure, mania, primary psychosis, delirium, medication effects, and sleep deprivation. Mechanistically interesting botanical serotonergic and adrenergic findings are not a validated psychiatric model for purified 7-OH. E13E14E28
Cardiac and respiratory risk are often interaction problems
Mechanistically plausible Reported 7-OH and broader kratom findings include tachycardia, hypertension, supraventricular tachycardia, and possible QT-related concerns. Mitragynine inhibited hERG current in vitro; an observational traditional-kratom study found more sinus tachycardia and borderline QTc, without more prolonged QTc. These data do not establish direct purified-7-OH cardiac dose-response or chronic cardiotoxicity. E29E32E33
Use particular caution with known long-QT syndrome, structural heart disease, syncope, significant arrhythmia, severe hypertension, electrolyte disturbance, stimulant co-use, methadone, or multiple QT-prolonging medicines. Obtain ECG and laboratory evaluation when clinically indicated; do not attribute chest pain, syncope, or sustained palpitations to withdrawal without assessment. E29E32E33
There are no dedicated 7-OH studies in OSA, COPD, central sleep apnoea, neuromuscular respiratory weakness, or obesity hypoventilation. Because 7-OH has demonstrated opioid respiratory effects, impaired ventilatory reserve and concurrent alcohol, benzodiazepines, gabapentinoids, sleep medicines, or other opioids should be treated as high-risk combinations. E23E24
Acute toxicity: rank the evidence, then treat the emergency
| Manifestation | What supports it | Honest interpretation |
|---|---|---|
| Respiratory depression | Controlled rat respiratory depression reversible with naloxone; one human cardiopulmonary-arrest report with naloxone-associated revival; poison-centre reports of breathing difficulty and loss of consciousness. | Established signal Incidence and human dose-response are unknown; coexposures and product uncertainty remain major limits. |
| Sedation, somnolence, loss of consciousness | Poison-centre surveillance and clinical cases. | Established signal Not a quantified incidence. |
| Nausea, vomiting, abdominal symptoms | Poison-centre surveillance and intoxication or withdrawal cases. | Commonly reported May occur in intoxication, withdrawal, or both. |
| Tachycardia, hypertension, urinary retention, or rhythm concerns | Surveillance, severe-use cases, and broader kratom evidence. | Possible Autonomic stress, withdrawal, coexposures, and product-specific constituents remain competing explanations. |
| Seizure, agitation, confusion, hallucinations, or psychosis | Surveillance and individual reports. | Serious but incompletely attributed Do not assume a single-agent syndrome. |
| Liver injury, endocrine, thyroid, reproductive, chronic renal, or chronic myocardial injury | Broader kratom observations or biological plausibility. | Not established for isolated 7-OH Do not place these in a list of proven chronic 7-OH harms. |
For an unresponsive person, abnormal or slow breathing, choking or gurgling sounds, or blue or grey colour: call 911, give naloxone if available, support breathing or begin CPR if trained, and stay with the person. Repeat naloxone according to the product instructions and local guidance if there is no response or recurrent sedation. Naloxone has reversed 7-OH-associated respiratory depression in preclinical work and was associated with revival in a reported human arrest. E23E24E52
A response supports opioid involvement; it does not identify the product, exclude co-ingestants, or end the need for observation. Unknown products and longer-lived co-ingestants can produce recurrent toxicity. E24E52
Emergency and acute-care management is supportive and presentation-directed: airway positioning, oxygenation, ventilation and capnography; titrated naloxone for clinically significant respiratory depression; continuous cardiorespiratory monitoring; ECG and targeted laboratory assessment; standard seizure treatment; coexposure assessment; and poison-centre or medical-toxicology consultation. Preserve the package or photograph it when feasible. Routine opiate immunoassays may be negative, and acute care should not wait for specialised testing. E09E10E23E24
Drug interactions: a real table, with real limits
Most interaction data derive from mitragynine or botanical kratom, not direct concentrated 7-OH. A labelled 7-OH tablet may still be chemically mixed, but it is not scientifically valid to promote every botanical or in-vitro interaction as a measured 7-OH interaction. E09E10E19E35
| Interacting agent or class | Mechanism or evidence | Clinical consequence | Action |
|---|---|---|---|
| Strong CYP3A inhibitors or inducers | With botanical mitragynine, CYP3A inhibition altered mitragynine exposure and 7-OH formation in controlled human work. Direct-ingested high-dose 7-OH is unstudied. | Do not presume a botanical result predicts direct 7-OH. | Reconcile medicines; seek pharmacy or toxicology input for a high-risk regimen. |
| CYP2D6 substrates | In a controlled low-dose botanical study, dextromethorphan showed no meaningful interaction; the effect at higher, chronic, or mixed exposures is unknown. | Data do not support a universal interaction prediction. | Monitor clinically after product or medicine changes rather than stopping necessary treatment indiscriminately. |
| Serotonergic agents: SSRI, SNRI, MAOI, triptan, tramadol, linezolid | Case-level concern exists with high-dose botanical kratom plus serotonergic medicines and inferred CYP inhibition; purified 7-OH has not shown clinically meaningful serotonergic agonism. | A defined 7-OH serotonin-syndrome risk is not established. | Review the regimen and seek urgent assessment for concerning symptoms. E13E36 |
| Benzodiazepines and Z-drugs | Additive CNS and respiratory depression. | Sedation, falls, aspiration, respiratory compromise, and a separate potentially dangerous sedative-withdrawal syndrome. | Avoid non-essential sedative stacking; assess alcohol and benzodiazepine withdrawal risk rather than placing a mixed case on a routine pathway. |
| Gabapentinoids, sedating antihistamines, antipsychotics, muscle relaxants, and sleep medicines | Additive sedation and impaired coordination; stacking sedatives can become its own hazard. | Falls, delirium, impaired alertness, or respiratory risk. | Assess indication, benefit, misuse risk, and co-use before adding sedating adjuncts. |
| Alcohol, other opioids, or fentanyl | Pharmacodynamic respiratory-depressant synergy; counterfeit products and illicit substitution remain practical concerns. | Highest overdose-risk combinations and added complexity for treatment planning. | Ask directly, provide naloxone, and choose a setting that can absorb the risk. |
| QT-prolonging agents, including methadone where relevant | Potential additive conduction risk in the setting of broader kratom cardiac signals, electrolyte disturbance, and polypharmacy. | Palpitations, syncope, or arrhythmia concern in a susceptible patient. | Review ECG and electrolyte risk when clinically indicated; do not stop needed treatment without an alternative plan. E32E33 |
| Naltrexone or products containing naltrexone | Opioid antagonism can precipitate withdrawal in a physiologically dependent person; a kratom case has been published. | Potential severe precipitated withdrawal; a validated opioid-free interval for direct high-dose 7-OH is unknown. | Verify all prescribed and combination products before treatment changes. E53 |
Polysubstance use is a risk multiplier
Alcohol, benzodiazepines, other opioids, fentanyl, gabapentinoids, sedating medicines, stimulants, and high-dose nicotine can each change the apparent syndrome. Ask what was used, how often, with what else, and what happens when supply ends. E01E28
Loss of a familiar retail source creates a specific fentanyl-substitution risk. Ask directly and non-judgementally whether the patient is considering illicit replacement; connect overdose education, naloxone, and timely addiction treatment to that conversation. A high-risk sedative combination does not justify withholding medication treatment for opioid use disorder, but it does require careful medication management. E51E54
Red flags and disposition
Call emergency services for unresponsiveness, slow or abnormal breathing, blue or grey colour, or a suspected overdose. Seek emergency assessment for seizure; altered mental status; syncope; chest pain; sustained palpitations; severe agitation or hyperthermia; jaundice; persistent vomiting or inability to maintain hydration; suspected muscle injury; suicidal intent; psychosis; or an unsafe withdrawal setting. E01E23E24E52
For a poisoning question or uncertain acute exposure in the United States, call Poison Help at 1-800-222-1222 while arranging clinically appropriate evaluation. E01
This page is educational and is not medical advice. It does not create a physician—patient relationship or replace an individual assessment. Seek an addiction medicine professional; use the buprenorphine prescriber finder to locate treatment support.